Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2023-07-25 Interim / Quarterly Rep…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 467.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q2 Progress Report' and includes detailed information about the company's progress in drug development programs, corporate activities, and a financial update including cash flow statements and capital raising details. It contains substantive financial data such as cash flows from operating, investing, and financing activities, as well as a reconciliation of cash and cash equivalents. The presence of a quarterly cash flow report (Appendix 4C) and detailed financial figures for the quarter ended 30 June 2023 indicates this is a comprehensive interim or quarterly financial report. The document is approximately 15,000 characters long, which is consistent with a full report rather than a brief announcement. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2023
2023-07-25 English
Successful Toxicology Results Pave Way for Phase 2 Trial 4 pages 303.9KB
Regulatory Filings Classification · 95% confidence The document is an announcement from PYC Therapeutics about the successful completion of non-clinical toxicology studies required to progress their drug candidate into a Phase 2 clinical trial. It details study results, doses, and safety findings, but it is not a financial report, earnings release, or regulatory filing related to financial performance. It is a clinical development update focusing on drug development progress and regulatory submission plans. This type of document is best classified as a Regulatory Filings (RNS) because it is a general regulatory announcement about clinical trial progress and non-financial study results, not fitting into other specific categories like earnings, capital updates, or management changes. The document length is sufficient and contains substantive information, but it is not a financial or governance report.
2023-07-17 English
Change in substantial holding 3 pages 119.4KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604' and references the Corporations Act 2001 Section 671B, which pertains to notices of change of interests of substantial holders. The content details changes in voting power, relevant interests, and shareholdings of a substantial holder in PYC Therapeutics Limited. It includes specific dates of changes, nature of changes (such as on-market purchases and issues pursuant to placements), and addresses of the substantial holders. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of 'Major Shareholding Notification' (Code: MRQ). The document is not a financial report, management announcement, or regulatory filing of other types, but specifically a substantial holder notice.
2023-07-17 English
Application for quotation of securities - PYC 6 pages 27.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from PYC Therapeutics Limited regarding the quotation of securities issued as part of a previously announced transaction. It references an Appendix 3B, which is a form used in Australian securities markets for new issues of securities. The document details the number of securities to be quoted, issue price, and issued capital following quotation. There is no financial report, earnings data, or management discussion. The content is focused on the issuance and quotation of new shares following shareholder approval. This fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other types of filings.
2023-07-13 English
Cleansing Notice Under Section 708AA 2 pages 220.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement notifying under section 708A(5)(e) of the Corporations Act 2001 about the issue of shares relating to a placement. It references the issuance of shares without disclosure under Part 6D.2 of the Act and confirms compliance with reporting obligations. The document is short (2735 characters) and serves as a formal notification of a capital raising event rather than a detailed financial report or presentation. It does not contain financial statements or detailed analysis but rather a regulatory notice about share issuance. Therefore, it fits best under Capital/Financing Update (CAP).
2023-07-13 English
Change of Director's Interest Notice 2 pages 241.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y' and is a 'Change of Director's Interest Notice' filed under ASX listing rule 3.19A.2. It details the change in securities held by a director, including the number of shares acquired and the value of the transaction. This type of document reports personal share transactions by company directors and executives, which matches the definition of 'Director's Dealing'. The document is not a full financial report, earnings release, or management report, nor is it an announcement of a report. It is a regulatory filing specific to insider trading disclosures.
2023-07-13 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.